CRINETICS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.51 USD | -4.02% |
|
-6.59% | +36.28% |
Presentation Operator MessageOperator (Operator)Welcome to the Crinetics Pharmaceuticals First...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
50.54
USD
Average target price
65.07
USD
Spread / Average Target
+28.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.28% | 3.99B | |
| +64.56% | 62.59B | |
| -1.11% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.39% | 26.21B | |
| -21.56% | 19.09B | |
| +4.89% | 13.08B | |
| +25.72% | 12.26B | |
| +28.57% | 12.05B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Transcript : Crinetics Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
